Press release from Companies
Published: 2025-11-17 13:45:00
The press release announced today at 13:00 CET was referring to a previous press release that Uppsala District Court has approved the Company’s request to extend its ongoing corporate reconstruction, the correct press release is that Svea Court of Appeal has rejected the Swedish Tax Agency’s request to terminate the Company’s corporate restructuring. Full press release below. Peptonic Medical AB (publ) ("the Company") announces that today the Svea Court of Appeal has rejected the Swedish Tax Agency’s request to terminate the Company’s corporate restructuring. The Court of Appeal has thereby upheld the District Court’s decision of 19 September 2025 to extend the Company’s corporate restructuring under the Swedish Corporate Restructuring Act (2022:964) until 16 December 2025.
For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic Medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
